Concepts of immunotherapy for glioma

Mira A. Patel, Andrew Mark Pardoll

Research output: Contribution to journalArticle

Abstract

Immunotherapy is coming to the fore as a viable anti-cancer treatment modality, even in poorly immunogenic cancers such as glioblastoma (GBM). Accumulating evidence suggests that the central nervous system may not be impervious to tumor-specific immune cells and could be an adequate substrate for immunologic anti-cancer therapies. Recent advances in antigen-specific cancer vaccines and checkpoint blockade in GBM provide promise for future immunotherapy in glioma. As anti-GBM immunotherapeutics enter clinical trials, it is important to understand the interactions, if any, between immune-based treatment modalities and the current standard of care for GBM involving chemoradiation and steroid therapy. Current data suggests that chemoradiation may not preclude the success of immunotherapeutics, as their effects may be synergistic. The future of therapy for GBM lies in the power of combination modalities, involving immunotherapy and the current standard of care.

Original languageEnglish (US)
Pages (from-to)323-330
Number of pages8
JournalJournal of Neuro-Oncology
Volume123
Issue number3
DOIs
StatePublished - Jul 23 2015

    Fingerprint

Keywords

  • Checkpoint
  • Glioblastoma
  • Glioma
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this